CombinAble.AI
Tailored Antibody Optimization
Company Overview
Snapshot
Founded in August 2023 by Daria Kokh, CombinAble.AI operates with 1–10 employees. The company was acquired by insitro in January 2026, following a funding round in March 2024.
Business overview
CombinAble.AI is a Health Tech & Life Sciences company that revolutionizes therapeutic design through its AI platform. The company's core technology enables the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers. By accelerating the development timeline for biologics, CombinAble.AI provides a competitive advantage to its partners in the biopharmaceutical, biotechnology, and pharmaceutical industries.
Strategic signal
In January 2026, CombinAble.AI was acquired by insitro, a move that significantly enhances insitro's capabilities by integrating CombinAble.AI's AI platform for targeted antibody design. This acquisition signals a strong market validation for AI-driven drug discovery platforms and underscores the growing trend of leveraging artificial intelligence to accelerate and optimize the development of complex therapeutics, offering a strategic advantage in the drug development landscape.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent corporate development for CombinAble.AI?
- CombinAble.AI was acquired by insitro in January 2026. This acquisition aimed to complete insitro's full-stack, modality-agnostic AI platform for drug discovery and design.
- When was CombinAble.AI founded and by whom?
- CombinAble.AI was founded in August 2023 by Co-founder & CEO Daria Kokh.
- What is CombinAble.AI's primary focus in therapeutic design?
- CombinAble.AI focuses on the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers, using its unique AI platform.
- What is the reported benefit of CombinAble.AI's platform for drug development?
- The platform enables the development of best-in-class therapeutics in approximately four months, significantly faster than traditional methods, providing a competitive advantage for complex biologics.